Traders Are Watching: Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR), Atlas Energy Group, LLC (NYSE:ATLS), Lipocine Inc. (NASDAQ:LPCN), Cleveland BioLabs, Inc. (NASDAQ:CBLI), Exlservice Holdings (NASDAQ:EXLS)

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) announced that William (Bill) Merino has been retained as a senior clinical and regulatory advisor to the company. Dr. Merino has extensive experience with the U.S. and global pharmaceutical approval process, quality assurance, and quality control, having served 33 years in senior regulatory affairs positions at Warner Lambert/Parke-Davis Pharmaceuticals, Alcon Pharmaceuticals, G. D. Searle & Co. and Riker Laboratories. He joins Ritter Pharmaceuticals, Inc. as the company focuses on moving its lead product, RP-G28, which is being developed for the treatment of lactose intolerance, into advanced Phase 2b/3 clinical trials. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) belongs to Healthcare sector. Its weekly performance is -10.25%. On last trading day company shares ended up $3.59. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) distance from 50-day simple moving average (SMA50) is -13.05%.

Atlas Resource Partners, L.P. (“ARP”) (ARP) announces that its syndicated lending group has reaffirmed the borrowing base of $750 million on ARP’s senior secured revolving credit facility. Atlas Resource Partners, L.P. (ARP) is an exploration & production master limited partnership which owns an interest in over 14,500 producing natural gas and oil wells, located primarily in Appalachia, the Barnett Shale (TX), the Mississippi Lime (OK), the Eagle Ford Shale (TX), the Raton Basin (NM), Black Warrior Basin (AL) and the Rangely Field (CO). Atlas Energy Group, LLC (NYSE:ATLS) shares moved down -18.25% in last trading session and ended the day at $2.15. ATLS Gross Margin is 56.70% and its return on assets is -5.70%. Atlas Energy Group, LLC (NYSE:ATLS) quarterly performance is -72.11%.

Lipocine Inc. (NASDAQ:LPCN), announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 35th Annual Canaccord Genuity Growth Conference on Wednesday, August 12, 2015 at 1:00 p.m. ET. A live audio webcast of the presentation will be available via the “Investor Relations” page of the Lipocine website, www.lipocine.com. Please log on through Lipocine’s website approximately 10 minutes prior to the scheduled start time. On 05 August, Lipocine Inc. (NASDAQ:LPCN) shares increased 0.77% and was closed at $13.06. LPCN EPS growth in last 5 year was 0.00%. Lipocine Inc. (NASDAQ:LPCN) year to date (YTD) performance is 148.29%.

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced that on August 12, 2015, it will report its financial results for the second quarter and six-month period ended June 30, 2015, and will host a conference call at 10:00 a.m. ET. Cleveland BioLabs, Inc. (NASDAQ:CBLI) ended the last trading day at $3.88. Company weekly volatility is calculated as 6.52% and price to cash ratio as 3.04. Cleveland BioLabs, Inc. (NASDAQ:CBLI) showed a weekly performance of -0.26%.

Exlservice Holdings, Inc. (NASDAQ:EXLS) announced its financial results for the second quarter of 2015. Revenues for the quarter ended June 30, 2015 were $155.6 million compared to $119.7 million for the quarter ended June 30, 2014 and $143.5 million for the quarter ended March 31, 2015. Revenues for the quarter ended June 30, 2014 were reduced by $5.7 million due to the reimbursement of disentanglement costs. Operations Management revenues for the quarter ended June 30, 2015 were $112.6 million compared to $94.3 million for the quarter ended June 30, 2014 and $110.7 Exlservice Holdings, Inc. (NASDAQ:EXLS) shares remains unchanged in last trading session and ended the day at $38.43. EXLS Gross Margin is 32.70% and its return on assets is 5.70%. Exlservice Holdings, Inc. (NASDAQ:EXLS) quarterly performance is 11.85%.

Leave a Reply

Your email address will not be published. Required fields are marked *